Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update

被引:9
作者
Khan, Sabiya Samim [1 ]
Khatik, Gopal L. [2 ]
Datusalia, Ashok K. [1 ,3 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmacol & Toxicol, Lucknow, India
[2] Natl Inst Pharmaceut Educ & Res NIPER Raebareli, Dept Med Chem, Lucknow, UP, India
[3] Natl Inst Pharmaceut Educ & Res NIPER Raebareli, Dept Regulat Toxicol, Lucknow, UP, India
关键词
Dementia; cognitive disorders; neurodegeneration; Alzheimer's disease; Parkinson's disease; schizophrenia; NICOTINIC ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE-C; VASCULAR COGNITIVE IMPAIRMENT; POSITIVE ALLOSTERIC MODULATOR; PLACEBO-CONTROLLED CROSSOVER; GLYCOGEN-SYNTHASE KINASE-3; RANDOMIZED CLINICAL-TRIAL; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; DOUBLE-BLIND;
D O I
10.2174/1570159X20666220411083922
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Memory, cognition, dementia, and neurodegeneration are complexly interlinked processes with various mechanistic pathways, leading to a range of clinical outcomes. They are strongly associated with pathological conditions like Alzheimer's disease, Parkinson's disease, schizophrenia, and stroke and are a growing concern for their timely diagnosis and management. Several cognition-enhancing interventions for management include non-pharmacological interventions like diet, exercise, and physical activity, while pharmacological interventions include medicinal agents, herbal agents, and nutritional supplements. This review critically analyzed and discussed the currently available agents under different drug development phases designed to target the molecular targets, including cholinergic receptor, glutamatergic system, GABAergic targets, glycine site, serotonergic targets, histamine receptors, etc. Understanding memory formation and pathways involved therein aids in opening the new gateways to treating cognitive disorders. However, clinical studies suggest that there is still a dearth of knowledge about the pathological mechanism involved in neurological conditions, making the dropouts of agents from the initial phases of the clinical trial. Hence, a better understanding of the disease biology, mode of drug action, and interlinked mechanistic pathways at a molecular level is required.
引用
收藏
页码:309 / 339
页数:31
相关论文
共 263 条
  • [1] Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia
    Aarsland, D
    Hutchinson, M
    Larsen, JP
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 (10) : 937 - 941
  • [2] PKC signaling deficits: a mechanistic hypothesis for the origins of Alzheimer's disease
    Alkon, Daniel L.
    Sun, Miao-Kun
    Nelson, Thomas J.
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (02) : 51 - 60
  • [3] Alrabiah Haitham, 2019, Profiles Drug Subst Excip Relat Methodol, V44, P167, DOI 10.1016/bs.podrm.2019.02.003
  • [4] Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy
    Ambrosius, Bjoern
    Gold, Ralf
    Chan, Andrew
    Faissner, Simon
    [J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (03):
  • [5] Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5 x FAD mouse model of Alzheimer's disease
    An, Jingjing
    Zhou, Yu
    Zhang, Mengjun
    Xie, Yunzhen
    Ke, Sujie
    Liu, Libin
    Pan, Xiaodong
    Chen, Zhou
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2019, 370
  • [6] First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer's Disease: A Randomized, Placebo-Controlled Study
    Andreasen, Niels
    Simeoni, Monica
    Ostlund, Henrik
    Lisjo, Pia I.
    Fladby, Tormod
    Loercher, Amy E.
    Byrne, Gerard J.
    Murray, Frances
    Scott-Stevens, Paul T.
    Wallin, Anders
    Zhang, Yinghua Y.
    Bronge, Lena H.
    Zetterberg, Henrik
    Nordberg, Agneta K.
    Yeo, Astrid J.
    Khan, Shahid A.
    Hilpert, Jan
    Mistry, Prafull C.
    [J]. PLOS ONE, 2015, 10 (03):
  • [7] [Anonymous], 2009, ALZHEIMERS DEMENT, DOI [10.1016/j.jalz.2009.04.925, DOI 10.1016/J.JALZ.2009.04.925]
  • [8] CREB activity maintains the survival of cingulate cortical pyramidal neurons in the adult mouse brain
    Ao, Hushan
    Ko, Shanelle W.
    Zhuo, Min
    [J]. MOLECULAR PAIN, 2006, 2
  • [9] Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production
    Arendash, G. W.
    Schleif, W.
    Rezai-Zadeh, K.
    Jackson, E. K.
    Zacharia, L. C.
    Cracchiolo, J. R.
    Shippy, D.
    Tan, J.
    [J]. NEUROSCIENCE, 2006, 142 (04) : 941 - 952
  • [10] Arlt Sonke, 2013, Dialogues Clin Neurosci, V15, P465